news 2021



Results 1 - 20 of 26.

Health - Pharmacology - 24.02.2021
Some men with testicular cancer may benefit from fewer CT scans
Patients who have had treatment for early-stage testicular cancer could benefit from fewer monitoring scans, reducing the harmful radiation they are exposed to from computerized tomography (CT) imaging, according to the results of a new clinical trial involving UCL researchers. Funded by Cancer Research UK and led by researchers at UCL, The Institute of Cancer Research, London, and Leeds/Huddersfield, the study found that using magnetic resonance imaging (MRI) instead of CT scans was as effective at picking up signs of cancer relapse.

Health - Pharmacology - 23.02.2021
Scientists launch a pre-emptive strike on deadly post-transplant infection
Scientists launch a pre-emptive strike on deadly post-transplant infection
A potential new treatment to protect  immunosuppressed  patients from human  cytomegalovirus  ( HCMV ) has been discovered by scientists at the University of Cambridge. Their study shows that certain epigenetic inhibitors expose and help to destroy dormant  HCMV  infections, which often reactivate to cause serious illness and death in these vulnerable groups.

Health - Pharmacology - 22.02.2021
Vaccine roll-out working, first national study
Vaccine roll-out working, first national study
Vaccination has been linked to a substantial reduction in the risk of Covid-19 admissions to Scotland's hospitals, landmark research suggests. The study is the first to describe across an entire country the effect of the Pfizer and Oxford-AstraZeneca jabs in the community on preventing severe illness resulting in hospitalisation.

Health - Pharmacology - 18.02.2021
Heart damage in half of COVID-19 patients with raised protein levels
More than 50% of patients hospitalised with COVID-19, who had raised levels of a protein called troponin, have some heart damage, finds a new magnetic resonance imaging study, led by UCL scientists. More than 50% of patients hospitalised with COVID-19, who had raised levels of a protein called troponin, have some myocardial injury (heart damage), finds a new magnetic resonance imaging study, led by UCL scientists.

Health - Pharmacology - 16.02.2021
Higher Covid-19 risk for middle-aged people with type 2 diabetes
A large-scale analysis involving UCL and funded by Diabetes UK has found a disproportionately higher Covid-19 death risk in middle-aged people with type 2 diabetes, raising questions over vaccination strategies across Europe. The study, published in the journal Diabetologia , found that compared to people of a similar age without type 2 diabetes, the additional COVID-19 mortality risk from having type 2 diabetes increases the younger someone is.

Health - Pharmacology - 16.02.2021
Oxford-led technology to help those at high risk from COVID-19
Oxford-led technology to help those at high risk from COVID-19
Research led by Professor Julia Hippisley-Cox in the University of Oxford's Nuffield Department of Primary Care Health Sciences, with collaborators across the UK, found that there are several health and personal factors which, when combined, could mean someone is at a higher risk from COVID-19. These include characteristics like age, ethnicity and BMI, as well as certain medical conditions and treatments.

Health - Pharmacology - 11.02.2021
Tocilizumab reduces deaths in patients hospitalised with COVID-19
The Randomised Evaluation of COVID-19 Therapy (RECOVERY) has demonstrated that an anti-inflammatory treatment, tocilizumab, reduces the risk of death when given to hospitalised patients with severe COVID-19. The study also showed that tocilizumab shortens the time until patients are successfully discharged from hospital and reduces the need for a mechanical ventilator.

Health - Pharmacology - 09.02.2021
Common asthma treatment reduces need for hospitalisation in COVID-19 patients, study suggests | University of Oxford
Early treatment with a medication commonly used to treat asthma appears to significantly reduce the need for urgent care and hospitalisation in people with COVID-19, researchers at the have found. The STOIC study found that inhaled budesonide given to patients with COVID-19 within seven days of the onset of symptoms also reduced recovery time.

Health - Pharmacology - 09.02.2021
COVID R&D response shows what’s possible for future healthcare and environmental innovation
New analysis of the R&D response to COVID argues that future innovation could be dramatically scaled up to tackle other major diseases or even climate change. Last updated on Tuesday 9 February 2021 Policymakers need to rethink their approach to tackling long-standing healthcare and environmental challenges and can learn lessons from the success of research and development in responding to COVID-19, say the authors of a new study.

Health - Pharmacology - 08.02.2021
Respiratory support used for COVID-19 patients produce less aerosol emission than breathing, speaking or coughing
Respiratory support used to treat patients with severe COVID-19 are associated with less aerosol emission than breathing, speaking or coughing new research suggests. The study led by researchers from the University of Bristol and North Bristol NHS Trust (NBT) is published on the pre-print server medRxiv.

Pharmacology - Health - 08.02.2021
Clinical trials begin to investigate treatment for diabetic eye disease
A new approach to treating one of the leading causes of blindness among patients with diabetes is being tested in clinical trials which begin this month. The trial involves 48 patient volunteers with diabetic macular oedema (DMO), a disease where blood vessels leak fluid into the retina. It is the most common cause of vision loss among people with diabetic retinopathy, affecting approximately 21 million people worldwide.

Health - Pharmacology - 05.02.2021
Severely frail individuals with COVID-19 are three times more likely to die
Severely frail individuals with COVID-19 are three times more likely to die
New research led by the University of Birmingham has revealed for the first time the extent to which frailty increases the risk of mortality in COVID-19 patients. The clinical observational study , involving 5,711 patients with COVID-19 at 55 hospitals across 12 countries, found that very severely frail individuals with COVID-19 are three times more likely to die than those who were not frail, even taking into account their age.

Health - Pharmacology - 02.02.2021
Latest review shows intensive care mortality from COVID-19 continued to fall in 2020, but improvement is slowing
A meta-analysis of global studies has shown that intensive care morality from COVID-19 has continued to fall since the start of the pandemic, but the improvement is slowing and may have plateaued. The study, published today [2 February] in Anaesthesia (a journal of the Association of Anaesthetists), is by Professor Tim Cook, Consultant in Anaesthesia and Intensive Care Medicine at the Royal United Hospitals Bath NHS Foundation Trust and Honorary Professor in Bristol Medical School: Translational Health Sciences (THS) at the University of Bristol, and colleagues.

Pharmacology - Health - 01.02.2021
Antipsychotic prescriptions rising much faster than psychosis rates
England has seen a modest rise in psychotic symptoms in recent years, while antipsychotic medication use doubled over the same period, according to a study by UCL and City, University of London researchers. The findings, published in Schizophrenia Research , clarify that a previously-reported rise in psychosis rates is partly, but not entirely, due to changes in prescription rates, as symptoms themselves are increasing as well.

Health - Pharmacology - 27.01.2021
Antibody highs and lows in survivors of Ebola
A high proportion of survivors of Ebola experienced a resurgence in antibody levels nearly a year after recovery, a new has found. Published today in Nature, the finding hints that hidden reservoirs of virus could exist long after symptoms ease and has implications for monitoring programmes and vaccine strategies.

Health - Pharmacology - 27.01.2021
Novel antiviral drug significantly more potent against SARS-CoV-2
The antiviral drug plitidepsin is between 10 and 100 times* more effective against SARS-CoV-2, including the new UK variant, than the NHS approved** drug remdesivir, finds new preclinical research involving UCL scientists. As part of a coronavirus collaboration with US researchers, a UCL team was asked to test the efficacy of the drug plitidepsin on the newly identified UK variant mutant strain B.1.1.7.

Pharmacology - Health - 27.01.2021
Engineers share model that could help clinicians safely ventilate two Covid-19 patients
Open-source model is shared to help medics around the world in case of ventilator shortfalls Last updated on Wednesday 3 February 2021 As Covid-19 continues to put pressure on healthcare providers around the world, engineers at the University of Bath have published a mathematical model that could help clinicians to safely allow two people to share a single ventilator.

Health - Pharmacology - 22.01.2021
Better post-surgical care would boost cancer survival chances
Better post-surgical care would boost cancer survival chances
Patients' chances of survival after cancer surgery is strongly linked with the standard of post-operation hospital care, a major international study suggests. Patients in low-and lower-middle-income countries were up to six times more likely to die from complications within 30 days of surgery compared with those in high-income countries, the report said.

Health - Pharmacology - 20.01.2021
Analysis: Big data can help doctors predict which Covid patients will become seriously ill
Professor Mahdad Noursadeghi (UCL Infection & Immunity) and Dr Rishi Gupta (UCL Institute for Global Health) discuss the importance of their new online 4C deterioration model, which is helping NHS doctors identify Covid-19 patients likely to deteriorate. The pandemic continues to pose huge challenges to health services worldwide.

Health - Pharmacology - 19.01.2021
Blood tests could bring new hope to Alzheimer’s clinical trials
A team of scientists at UCL have found that blood tests measuring the hallmark Alzheimer's protein, beta-amyloid (amyloid), could radically reduce the cost of clinical trials and potentially open the door to treating the disease earlier. The findings, published in the journal Brain , suggest that blood tests could be used to recruit people to Alzheimer's drug trials before they start showing any symptoms.

This site uses cookies and analysis tools to improve the usability of the site. More information. |